Search
Olodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalOlodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCopper
go.drugbank.com/drugs/DB09130ApprovedInvestigationalCopper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase [FDA Label]. Copper is commonly used in contraceptiv...
Mixtures: ADDAMEL NTechnetium Tc-99m sestamibi
go.drugbank.com/drugs/DB09161ApprovedInvestigationalTechnetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) l...
Categories: P-glycoprotein substratesLobeglitazone
go.drugbank.com/drugs/DB09198InvestigationalLobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. B...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsCiglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones....
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsTolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedTolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBlonanserin
go.drugbank.com/drugs/DB09223InvestigationalBlonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMelperone
go.drugbank.com/drugs/DB09224InvestigationalMelperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union . It h...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsBarnidipine
go.drugbank.com/drugs/DB09227InvestigationalBarnidipine is a long-acting novel calcium antagonist that belongs to the dihydropyridine (DHP) group of calcium channel blockers. Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors